Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | HTR7 | P34969 | 4/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.53 |
| ▸ | MLNR | O43193 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1838349 | 0.95 | RAB9A (0.70) | RAB9AMEN1CYP1A2KMT2ALMNA | |
| SCHEMBL11139092 | 0.94 | RAB9A (0.68) | RAB9AMEN1CYP1A2KMT2ALMNA | |
| SCHEMBL25315525 | 0.94 | RAB9A (0.68) | RAB9AMEN1CYP1A2KMT2ALMNA | |
| SCHEMBL8132581 | 0.94 | RAB9A (0.68) | RAB9AMEN1CYP1A2KMT2ALMNA | |
| SCHEMBL763168 | 0.90 | CYP1A2 (0.74) | RAB9AMEN1CYP1A2KMT2ALMNA | |
| SCHEMBL29695523 | 0.90 | CYP1A2 (0.74) | RAB9AMEN1CYP1A2KMT2ALMNA | |
| SCHEMBL30947438 | 0.90 | LMNA (0.78) | RAB9AMEN1CYP1A2KMT2ALMNA | |
| SCHEMBL6397082 | 0.83 | LMNA (0.69) | RAB9AMEN1CYP1A2KMT2ALMNA | |
| SCHEMBL318943 | 0.83 | LMNA (0.69) | RAB9AMEN1CYP1A2KMT2ALMNA | |
| SCHEMBL30277537 | 0.83 | LMNA (0.69) | RAB9AMEN1CYP1A2KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004039409-A2 | COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF | SWITCH BIOTECH AG (DE) | 2004-05-13 | — | — | WO | claimed |
| WO-2021226003-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2021-11-11 | — | — | WO | disclosed |
| EP-3138841-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-9156840-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-27 | — | — | US | disclosed |
| US-8691836-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2014-04-08 | — | — | US | disclosed |
| US-7446120-B2 | Peptidomimetic modulators of cell adhesion | ADHEREX TECHNOLOGIES, INC. (CA) | 2008-11-04 | — | — | US | disclosed |
| US-20080081831-A1 | PEPTIDOMIMETIC MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2008-04-03 | — | — | US | disclosed |
| US-7320993-B1 | Aryl-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic useful as cytostatic and immuosuppressive agents | ASTELLAS DEUTSCHLAND GMBH (DE) | 2008-01-22 | — | — | US | disclosed |
| US-7320993-B1 | Aryl-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic useful as cytostatic and immuosuppressive agents | ASTELLAS DEUTSCHLAND GMBH (DE) | 2008-01-22 | — | — | US | disclosed |
| WO-2004039409-A2 | COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF | SWITCH BIOTECH AG (DE) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | RAB9A 2363/4885MEN1 2011/4885CYP1A2 364/4885 |
| US-20080081831-A1 | PEPTIDOMIMETIC MODULATORS OF CELL ADHESION | CDH1, EPCAM, VCAM1 | RAB9A 2023/4885MEN1 792/4885CYP1A2 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.